Savara (SVRA)
(Delayed Data from NSDQ)
$3.96 USD
-0.06 (-1.49%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $3.96 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Savara Inc. [SVRA]
Reports for Purchase
Showing records 1 - 20 ( 48 total )
Company: Savara Inc.
Industry: Medical - Drugs
Molgramostim Near-Term Pivotal IMPALA-2 Topline Expected 2Q24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Savara Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Savara Inc.
Industry: Medical - Drugs
Molgramostim Advances With Phase 3 IMPALA-2 Topline Expected 2Q24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Molgramostim Pivotal IMPALA-2 Progress-Positioned for Success; PT Up to $6, Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Capitalized Beyond Pivotal aPAP Readout, IMPALA-2 Continues Onward; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Steady As She Goes-Phase 3 IMPALA-2 Trial on Track in aPAP; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Pivotal IMPALA-2 Trial in aPAP Continues As Planned; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Molgramostim IMPALA-2 Trial Remains on Track?Capitalized Through aPAP Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Continued Pivotal IMPALA-2 Progress For Nebulized Molgramostim in aPAP
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Steady As She Goes-Pivotal Molgramostim aPAP Progress; Opportunity for IMPALA-2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Progress Forward for Molgramostim in aPAP Remains on Track; Reit Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Company: Savara Inc.
Industry: Medical - Drugs
Company: Savara Inc.
Industry: Medical - Drugs
Refocused Strategy has IMPALA-2 at the Forefront Leading With Dosing of Patients Expected in 2Q/3Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Platform Refocused on Molgradex as the Path Forward; PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
IMPALA-2 Trial Design Finalized With 1Q21 Initiation; Reit Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Phase 3 for aPAP, With Expected De-Emphasis of NTM; Straightforward Story We Embrace Now More Than Ever
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Savara Inc.
Industry: Medical - Drugs
Looking Ahead to 2020: Further Molgradex Clarity in aPAP and NTM, and Phase 3 AVAIL Traction; Reit Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A